Meeting Banner
Abstract #0145

Immune Checkpoint Blockade (ICB) Response Evaluation with MRI/MR Elastography (MRE) in Surgical and Non-Surgical Patients with HCC

Aliya Qayyum1, Rony Avritscher2, Rizwan Aslam1, Jingfei Ma3, Mark Pagel4, Jia Sun5, Yehia Ibrahim Mohammed6, Manal Hassan7, Hesham Amin8, Asif Rashid9, Sunyoung Lee6, Robert A Wolff6, James C Yao6, Richard L Ehman10, Gabriel Daniel Duda11, and Ahmed Omar Kaseb12
1Radiology, MD Anderson, Houston, TX, United States, 2Interventional Radiology, MD Anderson, Houston, TX, United States, 3Imaging Physics, MD Anderson, Houston, TX, United States, 4Cancer Systems Imaging, MD Anderson, Houston, TX, United States, 5Biostatistics, MD Anderson, Houston, TX, United States, 6GI Medical Oncology, MD Anderson, Houston, TX, United States, 7Epidemiology, MD Anderson, Houston, TX, United States, 8Hemopathology, MD Anderson, Houston, TX, United States, 9Pathology, MD Anderson, Houston, TX, United States, 10Radiology, Mayo Clinic, Rochester, MN, United States, 11Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States, 12MD Anderson, Houston, TX, United States

Newer systemic treatments for advanced hepatocellular carcinoma (HCC) include immune checkpoint blockade (ICB) which act through increasing cytotoxic T-cell mediated response to tumor. There is a lack of biomarkers of ICB response and treatment outcomes are not correlated with change in tumor size. We evaluated MRI imaging features of HCC and change in tumor stiffness after 6 weeks immunotherapy in surgical and non-surgical patients. An increase in HCC stiffness on MRE after 6 weeks treatment was significantly correlated with treatment response. Longitudinal measurement of tumor stiffness on MRE provides a novel technique for early immunotherapy response assessment.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here